<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686385</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-DILI-001</org_study_id>
    <nct_id>NCT02686385</nct_id>
  </id_info>
  <brief_title>Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury</brief_title>
  <official_title>Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <brief_summary>
    <textblock>
      Intervention - Subjects will be randomized to 2 groups

      Group A - subjects will receive Prednisolone for 20 days with NAC (N-Acetylcysteine)

      Group B - will receive NAC (N-Acetylcysteine) only NAC (N-acetylcysteine) dosing

      Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1
      hour

      Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h

      Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h

        -  Monitoring and assessment-Liver Biopsy at baseline and at 3 months, Liver Function Test
           at regular intervals.

        -  Stopping rule-Development of sepsis, worsening of Liver functions.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Steroids were given for 2 patients who had biopsy proven Drug induced Liver Injury and both
    have them developed sepsis.
  </why_stopped>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 31, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with normalization of LFT (Liver Function Test) in both groups.</measure>
    <time_frame>20 days</time_frame>
    <description>Normalization of LFT (Liver Function Test) which is defined as Total bilirubin within normal limits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in of Histology.</measure>
    <time_frame>20 days</time_frame>
    <description>Improvement is defined as decrease in inflammation, decrease in cholestasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in CBC profile</measure>
    <time_frame>20 days</time_frame>
    <description>Improvement is defined normalization of CBC profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in coagulation profile</measure>
    <time_frame>20 days</time_frame>
    <description>Improvement is defined normalization of Coagulation profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in KFT profile</measure>
    <time_frame>20 days</time_frame>
    <description>Improvement is defined normalization of KFT profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients develop adverse effects in both groups.</measure>
    <time_frame>20 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Drug Induced Liver Injury</condition>
  <arm_group>
    <arm_group_label>Prednisolone + N-Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisolone for 20 days with NAC (N-Acetylcysteine) NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-Acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <arm_group_label>Prednisolone + N-Acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h</description>
    <arm_group_label>Prednisolone + N-Acetylcysteine</arm_group_label>
    <arm_group_label>N-Acetylcysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with severe DILI (Drug Induced Liver Injury)

          -  Age more than or equal to 18 years

        Exclusion Criteria:

          -  Patients with HAV (Hepatitis A Virus), HBV (Hepatitis B Virus), HCV (Hepatitis C
             Virus), HEV (Hepatitis E Virus) Positive

          -  Patients with sepsis

          -  AMA positive

          -  Low Ceruloplasmin

          -  Transferrin saturation &gt;45%

          -  Patients with Cirrhosis

          -  Patients with h/o jaundice prior to the intake of drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Anand Kulkarni V, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Chemical and Drug Induced Liver Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

